gsk

GSK completes acquisition of RAPT Therapeutics

GSK plc (LSE/NYSE: GSK) today announced the completion of its previously announced acquisition of RAPT Therapeutics, a California-based, clinical-stage biopharmaceutical company dedicated to ...
gsk

GSK to acquire potential best-in-class T cell-engager (TCE) for multiple myeloma from Chimagen Biosciences

GSK plc (LSE/NYSE: GSK) today announced it has entered an agreement to acquire a potential best-in-class trispecific T cell-engager (TCE) from Chimagen Biosciences (Chimagen), a privately held ...
gsk

GSK presents positive registrational data to potentially expand Jideytro (zidesamtinib) to first-line ROS1-positive non-small cell lung cancer

Results support potential to address key efficacy and tolerability needs in ROS1-positive NSCLC with US regulatory submission planned in 2026 GSK plc (LSE/NYSE: GSK) today announced positive results ...
gsk

ViiV Healthcare announces positive data demonstrating 2-drug regimen Dovato is as effective as 3-drug regimen Biktarvy for maintenance therapy of HIV-1

Largest head-to-head randomised clinical trial between DTG/3TC and BIC/FTC/TAF, conducted by SEIMC-GeSIDA Foundation (FSG) showed DTG/3TC demonstrated non-inferior efficacy compared to BIC/FTC/TAF as ...
gsk

GSK’s Omjjara (momelotinib) approved in Japan for treatment of myelofibrosis

Omjjara approved for use in both newly diagnosed or previously treated myelofibrosis patients Differentiated mechanism of action addresses key manifestations of myelofibrosis, namely anaemia, ...
gsk

European Commission approves expanded age indication for GSK’s Arexvy, the first respiratory syncytial virus (RSV) vaccine for adults aged 50-59 at increased risk

An estimated 20 million adults aged 50-59 in 30 European countries* have a medical condition that increases their risk for RSV disease 1-3 Authorisation helps protect this population for the first ...
gsk

Annual Governance Meeting

GSK plc hosted its annual governance meeting on Tuesday, 11 December 2024. This meeting provided an opportunity to engage with GSK’s investors and share an update on the work of our Board and ...
gsk

Analyst consensus

The consensus has been collated from estimates submitted by analysts to GSK using a standard template. The information is provided purely for convenience to users of our website, for information ...
gsk

GSK announces positive pivotal phase III data for next-generation low carbon version of Ventolin (salbutamol) metered dose inhaler

Data confirm therapeutic equivalence and comparable safety profile for Ventolin (salbutamol) containing innovative low carbon propellant Approximately 300 million salbutamol MDIs are sold globally ...
gsk

GSK accelerates oligonucleotide platform and pipeline medicines with acquisition of Elsie Biotechnologies

Oligonucleotides are a unique modality with potential to address hard-to-treat diseases with high unmet need Elsie’s platform technology will expand GSK’s broad oligonucleotide pipeline GSK plc ...
gsk

GSK delivers strong Q3 performance and upgrades 2025 guidance

Total Q3 2025 sales £8.5 billion +7% AER; +8% CER Specialty Medicines sales £3.4 billion (+16%); Respiratory, Immunology & Inflammation £1.0 billion (+15%); Oncology £0.5 billion (+39%); HIV sales ...
gsk

GSK announces positive results from DREAMM-7 head-to-head phase III trial for Blenrep in relapsed/refractory multiple myeloma

Blenrep (belantamab mafodotin) plus BorDex showed statistically significant progression-free survival (PFS) benefit versus daratumumab plus BorDex Trial unblinded early based on Independent Data ...